Literature DB >> 624295

Benign intracranial hypertension after minocycline therapy.

F Monaco, V Agnetti, R Mutani.   

Abstract

A case is reported of a young girl who developed benign intracranial hypertension, with severe bilateral papiledema and a left sixth cranial nerve palsy, after minocylcine therapy. This drug is a semisynthetic tetracycline which has proven to pass into the CSF more effectively and to have a greater lipoid solubility than the other antibiotics of the same group.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 624295     DOI: 10.1159/000114921

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  6 in total

1.  Doxycycline induced intracranial hypertension.

Authors:  J Lochhead; J S Elston
Journal:  BMJ       Date:  2003-03-22

2.  Not so benign intracranial hypertension.

Authors:  Kathleen B Digre
Journal:  BMJ       Date:  2003-03-22

3.  Increased Incidence of Pseudotumor Cerebri Syndrome Among Users of Tetracycline Antibiotics.

Authors:  Samuel F Passi; Ryan Butcher; Daniel R Orme; Judith E A Warner; Gregory J Stoddard; Alison V Crum; Ramkiran Gouripeddi; Brian H Kirk; Kathleen B Digre; Bradley J Katz
Journal:  J Neuroophthalmol       Date:  2022-03-25       Impact factor: 4.415

4.  Congenital protein C deficiency and superior sagittal sinus thrombosis causing isolated intracranial hypertension.

Authors:  C Confavreux; P Brunet; P Petiot; M Berruyer; M Trillet; G Aimard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

5.  Minocycline-associated pseudotumor cerebri with severe papilledema.

Authors:  Simon R Bababeygy; Michael X Repka; Prem S Subramanian
Journal:  J Ophthalmol       Date:  2010-02-16       Impact factor: 1.909

6.  A Population-Based, Case-Control Evaluation of the Association Between Hormonal Contraceptives and Idiopathic Intracranial Hypertension.

Authors:  Khin P Kilgore; Michael S Lee; Jacqueline A Leavitt; Ryan D Frank; Collin M McClelland; John J Chen
Journal:  Am J Ophthalmol       Date:  2018-09-21       Impact factor: 5.258

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.